BioLineRX signs deals with PolyGene and Efrat Biopolymers
Drug development company BioLineRx has entered into worldwide license agreements with fellow Israeli firms PolyGene and Efrat BioPolymers, which will see the development and commercialization of the former's polymer drug-delivery system.
BioLineRx said that it will continue to develop the system for use in the delivery of chemotherapy to solid tumors (BL-4010), as well as in the administration of antibiotics for the treatment of bone infections (BL-4011). The firm added that it intends to submit a funding request for the project to the Israel's Office of the Chief Scientist through its BioLine Innovations subsidiary.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze